Knight Therapeutics Faces Financial Challenges Amid Valuation Score Revision

Knight Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in evaluation that reflects a shift in its financial standing. The company's valuation score has been revised, indicating a change in its perceived market position.
Key financial metrics reveal that Knight Therapeutics is currently facing challenges. The P/E ratio remains unavailable due to the company being loss-making, while the Price to Book Value stands at 0.82. The EV to EBIT ratio is notably negative at -71.19, and the EV to EBITDA is recorded at 15.15. Additionally, the EV to Sales ratio is 1.66, suggesting a complex valuation landscape.

The company's return on capital employed (ROCE) and return on equity (ROE) are both in negative territory, at -1.16% and -0.11%, respectively. Furthermore, the financial performance for the quarter ending June 2025 has been categorized as very negative, with a significant decline in profit before tax (PBT) and rising costs impacting overall results.

In light of these developments, Knight Therapeutics, Inc. has seen a revision in its score, reflecting the current financial dynamics at play.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.